Beovu is a new FDA approved medication for the treatment of wet age-related macular degeneration. It is administered in the same manner as the currently used FDA approved medications Lucentis and Eylea.
Beovu has been demonstrated to last longer and be as good as Eylea in improving vision in patients with wet age-related macular degeneration.
Greater than 50% of patients in the Beovu clinical trial were able to be maintained on treatment every 3 months.
The side effect profile of Beovu is very similar to Eylea. Approximately 2% of patients in the clinical trial experienced inflammation within the eye. This is higher than the 0.2% incidence with Eylea. Greater than 90% of patients had complete resolution of inflammation with topical anti-inflammatory eye drops.